Abstract
Paying a huge premium to acquire an on-market asset with multi billion dollar revenue potential, AbbVie has trumped Johnson & Johnson (J&J) with a US$21 B deal to acquire Pharmacyclics. Key to the acquisition is Imbruvica® (ibrutinib), a Bruton’s tyrosine kinase (Btk) inhibitor that is approved for a number of B-cell malignancies.The purchase price has shocked many industry observers, effectively valuing Imbruvica as it does at a staggering US$42 B given J&J’s 50% interest in the drug. After being forced to halt its bid to acquire Shire, the deal is another attempt by AbbVie to diversify its business beyond Humira® (adalimumab).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
